Complement and cancer: activation of the alternative pathway as a theoretical base for immunotherapy.
Activation of the APC is pointed out as the common factor in all sufficiently studied cancer treatments employing nonspecific, active immunotherapy. This chapter outlines the molecular biology of both APC and classical pathway of complement, summarizes the alternative pathway's biologic activities especially in relation to the C3/C5 convertase C3b,Bb, and its implications in the mechanism of host defense against malignancies, particularly relating to the activated macrophage. The many involvements of the APC in the various agents used for nonspecific active immunotherapy are reviewed, and possible clinical implications outlined. It is concluded that activation of the APC can be proposed as the specific theoretical basis so far lacking for this treatment modality and that it is accordingly feasible to attempt to monitor clinical application of this principle by fine-tuning of APC activation in cases of human cancer.
D000276:Adjuvants, Immunologic; D003167:Complement Activation; D003170:Complement Pathway, Alternative; D003165:Complement System Proteins / Q000502:physiology*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D008214:Lymphocytes / Q000502:physiology; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology; D009369:Neoplasms / Q000503:physiopathology* / Q000628:therapy
D000276:Adjuvants, Immunologic; D003165:Complement System Proteins